Ser353
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser353  -  PSEN1 (human)

Site Information
sHLGPHRstPEsRAA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448562
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 11 , 12 ) , immunoprecipitation ( 11 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , mutation of modification site ( 10 , 11 , 12 ) , peptide sequencing ( 12 )
Disease tissue studied:
lung cancer ( 1 , 2 , 3 , 4 ) , non-small cell lung cancer ( 2 , 4 , 5 , 6 ) , non-small cell lung adenocarcinoma ( 2 , 3 , 4 , 6 ) , non-small cell large cell lung carcinoma ( 2 ) , non-small cell squamous cell lung carcinoma ( 3 ) , small-cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 10 , 11 ) , Cal-12T (pulmonary) ( 4 ) , DMS53 (pulmonary) ( 1 ) , HCC15 (pulmonary) ( 3 ) , HCC44 (pulmonary) ( 4 ) , HEK293T (epithelial) ( 12 ) , Jurkat (T lymphocyte) ( 7 , 8 , 9 ) , LOU-NH91 (squamous) ( 3 ) , lung ( 1 , 2 , 3 , 4 ) , NCI-H1299 (pulmonary) ( 2 ) , NCI-H1437 (pulmonary) ( 4 ) , NCI-H1666 (pulmonary) ( 4 ) , NCI-H1703 (squamous) ( 3 ) , NCI-H1734 (pulmonary) ( 2 ) , NCI-H1944 (pulmonary) ( 2 ) , NCI-H2073 (pulmonary) ( 3 ) , NCI-H2228 (pulmonary) ( 6 ) , NCI-H2342 (pulmonary) ( 3 ) , NCI-H2405 (pulmonary) ( 4 ) , NCI-H3122 (pulmonary) ( 5 ) , NCI-H358 (pulmonary) ( 2 ) , NCI-H446 (pulmonary) ( 1 ) , NCI-H460 (pulmonary) ( 2 ) , NCI-H526 (pulmonary) ( 1 ) , NCI-H69 (pulmonary) ( 1 ) , NCI-H82 (pulmonary) ( 1 )

Upstream Regulation
Putative in vivo kinases:
GSK3B (human) ( 10 , 11 )
Kinases, in vitro:
GSK3B (human) ( 11 , 12 )
Treatments:
GSK-3_inhibitor_VIII ( 11 ) , okadaic_acid ( 11 )

Downstream Regulation
Effects of modification on PSEN1:
intracellular localization ( 10 ) , molecular association, regulation ( 10 , 12 ) , protein conformation ( 11 )
Effects of modification on biological processes:
cell growth, altered ( 11 )
Induce interaction with:
CTNNB1 (human) ( 12 )
Inhibit interaction with:
CDH2 (human) ( 10 ) , CTNNB1 (human) ( 10 , 11 )

References 

1

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K (2013) CST Curation Set: 18860; Year: 2012; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

6

Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

7

Zhou J (2011) CST Curation Set: 12497; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Possemato A (2008) CST Curation Set: 5273; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

9

Possemato A (2008) CST Curation Set: 5275; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

10

Uemura K, et al. (2007) GSK3beta activity modifies the localization and function of presenilin 1. J Biol Chem 282, 15823-32
17389597   Curated Info

11

Prager K, et al. (2007) A structural switch of presenilin 1 by glycogen synthase kinase 3beta-mediated phosphorylation regulates the interaction with beta-catenin and its nuclear signaling. J Biol Chem 282, 14083-93
17360711   Curated Info

12

Kirschenbaum F, Hsu SC, Cordell B, McCarthy JV (2001) Substitution of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signaling. J Biol Chem 276, 7366-75
11104755   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.